Introduction of Novavax/Nuvaxovid XBB.1.5
As of May 28, Singaporeans have access to a new option for COVID-19 vaccination: the Novavax/Nuvaxovid XBB.1.5 vaccine. Announced by the Ministry of Health (MOH), this addition to the National Vaccination Programme (NVP) is part of Singapore’s ongoing efforts to provide the public with effective means to combat COVID-19.
Vaccine Availability and Eligibility
The vaccine is available free of charge to eligible individuals at selected general practitioner (GP) clinics that participate in the Covid-19 vaccination drive. Approved by the Health Sciences Authority, the Novavax/Nuvaxovid XBB.1.5 vaccine is recommended for individuals aged 12 and above, aligning with the prevailing COVID-19 vaccination recommendations.
The introduction of the Novavax/Nuvaxovid XBB.1.5 vaccine broadens the array of COVID-19 vaccines available to Singaporeans, offering more choices to meet public health needs. As the situation evolves, the MOH continues to adapt its strategies to ensure optimal health outcomes for the community.
Also learn about Surging Demand for COVID-19 Test Kits in Singapore Amid New Infection Wave.
